As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

The FDA has identified critical lapses at a production facility operated by Novo Nordisk that is used by several drugmakers, ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

A major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, the FDA found in a ...

The products reported missing include insulin formulations marketed as Ryzodeg FlexTouch and Fiasp (Penfill and FlexTouch), ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

The regulator in its health alert letter mentioned that these stolen drugs are rDNA injectables that require strict ...